Effects of angiotensin type 1 receptor antagonists on Parkinson?s disease progression: An exploratory study in the PPMI database

LUCAS UDOVIN , MATILDE OTERO-LOSADA, SOfiA BORDET, GUENSON CHEVALIER , CECILIA QUARRACINO , FRANCISCO CAPANI , SANTIAGO P´EREZ-LLORET

Parkinsonism and Related Disorders

Elvesier

Año: 2021

1873-5126

Introduction: We explored the potential clinical effects of angiotensin-II AT1 receptor blockers (ARBs) andangiotensin-converting enzyme inhibitors (ACEIs) in patients from the Parkinson?s Progress Marker Initiative(PPMI) study database.Methods: We included 423 newly diagnosed PD patients, free from antiparkinsonian treatment, from the PPMI.We compared the proportion of patients starting on L-DOPA during the first year of follow-up, and the changes inMDS-UPDRS total score and sub-scores during the first five follow-up years for patients exposed or not to ARBs orACEIs.Results: Treatment with ARBs did not affect the proportion of patients on L-DOPA during the first year (adjustedOR, 95% CI = 0.26, 0.03?2.18, N.S.) while reduced MDS-UPDRS total score (0.85, 0.76?0.95, p < 0.01). Patientstreated with ACEIs experienced no changes in either measure.Conclusions: These results show potential signals for a beneficial effect with ARBs. Further clinical trials arewarranted.